Advancing workforce diversity by leveraging the Clinical and Translational Science Awards (CTSA) program

Locklear, Tracie; Lewis, Roslyn; Calhoun, Faye; Li, Andy; Dickerson, Kathryn C.; McMillan, Amanda E.; Davis, Lisa; Dzirasa, Kafui; Weinfurt, Kevin P.; Grambow, Steven C.

doi:10.1017/cts.2022.489

Cited by 3 publications

(4 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This creates a division between the patients and the providers and can lead to mistrust. Interventions to diversify staff through programs meant to mentor students and trainees in the early stages of their careers shows substantial promise [33]. Understanding how PC3 can undertake or contribute to efforts to increase representation in local cancer center research staff could ultimately lead to increased participation of underrepresented communities in cancer clinical trials [34].…”

Section: Discussionmentioning

confidence: 99%

Developing a city-wide, community-engaged cancer disparities research agenda

Leader,

Song,

González

et al. 2024

Preprint

View full text Add to dashboard Cite

Introduction: In response to high levels of cancer disparities in Philadelphia, PA, three NCI-designated clincal cancer centers formed Philadelphia Communities Conquering Cancer (PC3) to bring stakeholders together and establish infrastructure for future cancer reducing initiatives. The PC3 coalition aimed to develop a prioritized cancer disparities research agenda in order to align cancer center resources and research interests with the concerns of the community about cancer, and to ensure that initiatives were patient- and community-centered. Methods: Agenda development activities culminated in a city-wide cancer disparities conference. The conference, attended by 55 diverse stakeholders, was the venue for small group discussion sessions about cancer concerns related to prevention, early detection, treatment, survivorship and quality of life. Sessions were guided by a moderator guide and were audiorecorded, transcribed, and analyzed by the PC3 leadership team. Results were reviewed and consensus was achieved with the help of PC3’s Stakeholder Advisory Committee. Results: Stakeholders identified four thematic areas as top priorities for cancer disparities research and action in Philadelphia: communication between patients, providers, and caregivers; education that reaches patients and community members with tailored and targeted information; navigation that assists people in finding and accessing the right cancer screening or treatment option for them; and representation that diversifies the workforce in clinics, cancer centers, and research offices. Conclusion: A community-informed, prioritized research agenda provides a road map for the three cancer centers to collaborate on future initiatives that are important to patients and stakeholders, to ultimately reduce the burden of cancer for all Philadelphians.

show abstract

Section: Discussionmentioning

confidence: 99%

Developing a city-wide, community-engaged cancer disparities research agenda

Leader,

Song,

González

et al. 2024

Preprint

View full text Add to dashboard Cite

show abstract

“…Several manuscripts focus on leadership in clinical and translational science, and they describe efforts to leverage the CTSA program including building upon work started at the 2020 annual meeting to address workforce development and to provide support for more equitable leadership opportunities for underrepresented minorities (URM). This includes critical initiatives which have elevated the CTSA Diversity, Equity, Inclusion, and Accessibility (DEIA) Task Force to a standing committee for the national CTSA consortium [3][4][5]. Papers also identify crucial roadblocks to achieving DEI goals.…”

Section: Leadershipmentioning

confidence: 99%

Laying the groundwork to make diversity, equity, and inclusion front and center in clinical and translational research

Egede

Ruiz

Mosley-Johnson

et al. 2023

J. Clin. Trans. Sci.

View full text Add to dashboard Cite

“…Improve diversity and retention in the clinical trial workforce. This effort is a strong emphasis for the Clinical and Translational Science Award program [ 8 ]. While acknowledging the challenges of recruiting a representative workforce, it is essential to prioritize diverse participant recruitment for more impactful and generalizable scientific outcomes [ 8 ].…”

Section: Diversifying and Sustaining Research Teams And Workforcementioning

confidence: 99%

“…This effort is a strong emphasis for the Clinical and Translational Science Award program [ 8 ]. While acknowledging the challenges of recruiting a representative workforce, it is essential to prioritize diverse participant recruitment for more impactful and generalizable scientific outcomes [ 8 ]. Institutions that have difficulty recruiting and retaining diverse workers will likely have trouble recruiting diverse participants.…”

Section: Diversifying and Sustaining Research Teams And Workforcementioning

confidence: 99%

Diversity, equity, inclusion, and access are necessary for clinical trial site readiness

Carter-Edwards,

Hidalgo,

Lewis-Hall

et al. 2023

J. Clin. Trans. Sci.

View full text Add to dashboard Cite

Clinical research has long struggled with diversity, equity, inclusion, and access (DEIA). Despite the increasing diversity of the U.S. population, marginalized groups continue to be underrepresented in clinical trials. The lack of representation in clinical trials has impeded innovation, compromised generalizability of evidence, and may undermine trust in the clinical trials enterprise [1]conclusions that FDA echoes in its guidance on diversity plans [2]. DEIA must inform clinical trials from design to dissemination to generate valid, generalizable evidence that meets the needs of an increasingly diverse population and addresses health inequities.In this commentary, we discuss select site readiness practices, outlined in a companion article [3], which are particularly relevant to promoting DEIA in clinical trials. This perspective focuses on race and ethnicity, though other aspects of diversity, such as ability, sex, gender, sexual orientation, and others, also are underrepresented in clinical research [1,4]. Addressing race and ethnicity is an opportunity to intentionally focus efforts on a long-standing area of exclusion in clinical trials. The companion article includes the full set of site readiness practices, methods for their selection, and a rationale for their use by clinical trial sites. Site readiness practices must include DEIA considerations to avoid perpetuating existing inequities and to help address known or suspected barriers to clinical trials accesssuch as language, transportation, or dependent care [5]. Additionally, site readiness practices should seek to address structural constructs perpetuated within the medical and clinical trial enterprise that impede progress on these issuesthrough insurance coverage, hiring practices, partnership with communities, and mentorship opportunities. To this point, improving DEIA should specifically and explicitly be expressed as both goals and metrics for progress. Effective DEIA efforts in research participation should begin early, during the design and budgeting stages. Site readiness often involves actions taken even before the project's conceptualization, such as modifying existing systems or policies. We believe that the site readiness practices discussed in this article (Table 1) support the development of a clinical research system that is intentionally inclusive, and therefore more closely aligned with the needs of patients.

show abstract

Advancing workforce diversity by leveraging the Clinical and Translational Science Awards (CTSA) program

Abstract: This version may be subject to change during the production process.

Cited by 3 publications

References 9 publications

Developing a city-wide, community-engaged cancer disparities research agenda

Developing a city-wide, community-engaged cancer disparities research agenda

Laying the groundwork to make diversity, equity, and inclusion front and center in clinical and translational research

Diversity, equity, inclusion, and access are necessary for clinical trial site readiness

Contact Info

Product

Resources

About